Gene editing technology marks a major breakthrough for gene therapy. However, current gene delivery systems, such as viral transfection, do not work efficiently for many important biomedical applications and lack the precision required to target specific cancer cells in complex microenvironments and tissues. 

To address this issue, Xcycles is developing a novel microfluidic approach to formulate bioinspired cell-membrane nanovesicles (CMNVs) as cargo carriers. Our focus is on the development of personalized nanovesicles from primary cells (e.g., platelets, blood cells, and cancer cells isolated from patients) by using an integrateable microfluidic workflow. Next to vesicle fabrication, we study transmembrane binding affinity, mechanism, and specificity to formulate smart nanocarriers with a high circulation time and precise delivery of therapeutics, thereby minimizing side effects. Our research plan aims to establish a scalable, state-of-the-art biomedical engineering technology that supports organ-specific gene editing and antibiotic therapy.